FY2024 EPS Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Boosted by Leerink Partnrs

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities researchers at Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.32) per share for the year, up from their prior forecast of ($0.43). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.06) EPS.

A number of other research firms also recently issued reports on FULC. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, September 12th. Bank of America downgraded Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price target for the company from $10.00 to $2.00 in a research report on Thursday, September 12th. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $22.00 to $3.00 in a research report on Thursday, September 12th. HC Wainwright downgraded Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $17.00 to $4.00 in a research report on Friday. Finally, Royal Bank of Canada downgraded Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $15.00 to $4.00 in a research report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.33.

Fulcrum Therapeutics Stock Performance

FULC stock opened at $3.18 on Monday. The stock has a 50-day moving average price of $8.35 and a two-hundred day moving average price of $8.21. Fulcrum Therapeutics has a 12-month low of $2.87 and a 12-month high of $13.70. The company has a market cap of $197.65 million, a PE ratio of -1.99 and a beta of 2.23.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The firm had revenue of $80.00 million during the quarter, compared to the consensus estimate of $80.00 million. During the same quarter in the previous year, the business earned ($0.38) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FULC. Capstone Investment Advisors LLC acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $68,000. Affinity Asset Advisors LLC acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $844,000. Vestal Point Capital LP acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $6,919,000. ADAR1 Capital Management LLC acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $4,302,000. Finally, Opaleye Management Inc. acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $878,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.